INTRODUCTION: Hepatocellular cancer or hepatocellular carcinoma (CHC) is the 5th most
common cancer in men and the 7th in women, being 4-8 times more common in men than in
women, with a peak incidence of 70 years. The most important risk factor for the
development of CHC is cirrhosis, with hepatitis B and C viruses being the main etiological
agents involved in the development of CHC, in about 70 to 80% of cases. OBJECTIVE: To
investigate the role of polymorphisms in the ABCC2 and GGH genes in patients with chronic
hepatitis B and C viruses and hepatocellular carcinoma (CHC). METHODOLOGY: A cross sectional, observational and descriptive study was carried out from July 2022 to July 2023
using the RedCap system. RESULTS: 59 patients participated in this study, 69.49% were
male, 2 cases (5.71%) of hepatocellular carcinoma were identified in the ABBC2 gene group
(rs717620) and 1 case (4.16%) in the GGH group (rs3758149). As for the genotypic
characterization of gene polymorphisms, a frequency of 80% of the C/C profile was observed
in the ABCC2 gene group and a frequency of 58.3% of the A/A and A/G profiles in the GGH
gene group. CONCLUSION: There was a higher prevalence of individuals diagnosed with
infection by the hepatitis B and C viruses compared to other causes of chronic liver disease,
most of whom were males aged over 60 years. As for the identified polymorphisms, a higher
prevalence of the C/C genotypic profile was identified in patients with chronic liver diseases
due to various causes, in the ABCC2 gene (rs717620), and a higher prevalence of the A/A
genotypic profile, in the GGH gene (1801133) and with loss of weight, abdominal pain, bone
pain and jaundice.
|
